A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.
Matthew J. Matasar, MD
Advertisement
Matthew J. Matasar, MD, is a hematologist/oncologist and chief, Division of Blood Disorders, at the Rutgers Cancer Institute, as well as a professor of medicine at Rutgers Robert Wood Johnson Medical School.
Articles by Matthew J. Matasar, MD
Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.
Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.
Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.
Matthew J. Matasar, MD, discusses the current landscape of diffuse large B-cell lymphoma.
Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.
Matt Matasar, MD, discusses treatment options in B-cell lymphomas.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5
